The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Trikafta has become Vertex’s (Nasdaq: VRTX) blockbuster CF drug, helping drive its product revenue to $9.87 billion last year. Alyftrek is approved for CF patients 6 years and older who have at ...

Alyftrek’s approval is based on clinical data comparing the once-daily therapy to Trikafta, a Vertex triple combination drug initially approved in 2019 as a twice-daily CF treatment. Results ...

The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex’s other CF medicines. Similar regulatory filings are also under review in Europe. However, the drug’s ...

Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome, an NIH-funded study showed. CMS has selected 15 new drugs for the ...

A classic example is the expansion of the blockbuster drug Trikafta to treat CF patients aged just two years or more, significantly boosting the size of its target market after being initially ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the SKYLINE 102 and SKYLINE 103 trials, which showed that Alyftrek matched ...